When was DeNovX founded?

DeNovX was founded in 2011 and raised its 1st funding round 4 years after it was founded.

Where is DeNovX located?

DeNovX is headquartered in Chicago, United States.

How many employees does DeNovX have?

As of Mar 31, 2026, the latest employee count at DeNovX is 3.

Is DeNovX a funded company?

DeNovX is a funded company, having raised an undisclosed amount across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 10, 2015.

When was the latest funding round of DeNovX?

DeNovX's latest funding was a $***** Grant (prize money) round on Mar 11, 2025, with participation from 1 investor.

Where does DeNovX rank among its competitors?

DeNovX ranks 2225th amongst 2500 active competitors, of which 856 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was DeNovX, which secured $350K in Sep, 2024.

Who are the top competitors of DeNovX?

DeNovX's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, DeNovX secured the most recent funding round in March, 2025.

DeNovX - 2026 Company Profile, Team, Funding & Competitors

DeNovX is a funded company based in Chicago (United States), founded in 2011 by Andrew Bond. It operates as a Pharmaceutical company that provides platform products for pharmaceutical and medical nutrition uses. DeNovX has raised an undisclosed amount in funding. The company has 2500 active competitors, including 856 funded and 629 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

DeNovX is an innovative pharmaceutical company that provides platform products for pharmaceutical uses. Its pharmaceutical products division is advancing the development of a treatment for ulcerative colitis. The lead product for the same is DNVX-078, for the treatment of mild-to-moderate ulcerative colitis (UC), with platform extension opportunities into other diseases

Website: denovx.com
Email ID: *****@denovx.com

Key Metrics

Founded Year

2011

Location

Chicago, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Mar 11, 2025, $*****

Investors

HHS

Ranked

2225^th among 2500 active competitors

Employee Count

3 as on Mar 31, 2026

Similar Companies

RedHill Biopharma & 146 more

View DeNovX's full profile

DeNovX has raised funding over 9 rounds. Its first funding round was on Jan 10, 2015. Its latest funding round was a Grant (prize money) round on Mar 11, 2025 for $*****. 1 investor participated in its latest round. DeNovX has 1 institutional investor.

Here is the list of recent funding rounds of DeNovX:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 11, 2025	1553235	Grant (prize money)	7846988	8266044	2310927	1904235
Sep 18, 2024	3807995	Grant (prize money)	6048409	7957776	6250130	HHS
Sep 30, 2022	9063187	Grant (prize money)	2073317	9136530	6911448	HHS

Access funding benchmarks and valuations. Sign up today!

View details of DeNovX's funding rounds and investors

The founders of DeNovX is Andrew Bond.

Here are the details of DeNovX's key team members:

Andrew Bond: Co-Founder & COO of DeNovX.
Contact Info: 1 email address

View details of DeNovX's Founder profiles and Board Members

DeNovX's employee count trend

DeNovX has 3 employees as of Mar 26. Here is DeNovX's employee count trend over the years:

Uncover DeNovX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DeNovX include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of DeNovX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
8th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
10th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
2225th	DeNovX 2011, Chicago (United States), Funding Raised	Pharmaceutical company that provides platform products for pharmaceutical and medical nutrition uses	-	HHS	22/100